CD163 and neoplasm: Using mIF, we confirmed that IRX-2 is associated with increases in sTILs and PD-L1 upregulation in the tumor microenvironment, as well as a shift in the ratio of cytotoxic T cells to CD163+ macrophages and regulatory T cells.